Lanzo Melt

Lansoprazole, the active ingredient in Lanzo Melt, is a proton pump inhibitor presented as an oral formulation for systemic use. It reduces gastric acid production and is indicated for the treatment of acid‑related disorders such as gastro‑esophageal reflux disease, peptic ulcer disease and erosive esophagitis in adult patients.

GNH USA supplies Lanzo Melt as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution across the European Union market. The company adheres to stringent quality standards and provides regulatory support for importers.

Lansoprazole is used to manage acid‑related gastrointestinal conditions by suppressing gastric acid secretion.

- Gastroesophageal reflux disease (GERD): reduces acid exposure to relieve heartburn and esophageal irritation. - Peptic ulcer disease: promotes ulcer healing by decreasing gastric acidity. - Erosive esophagitis: allows damaged esophageal tissue to recover through acid suppression. - Helicobacter pylori eradication regimen: enhances the effectiveness of antibiotic therapy when used as part of combination treatment.

Lansoprazole may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often transient. - Diarrhea: loose stools occurring during treatment. - Abdominal pain: discomfort or cramping in the stomach area. - Nausea: feeling of sickness or urge to vomit. - Flatulence: increased intestinal gas. - Constipation: difficulty passing stool.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis with watery diarrhea. - Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing. - Liver enzyme elevation: increased ALT/AST indicating hepatic stress. - Low magnesium levels: may cause muscle weakness or irregular heartbeat. - Bone fracture risk: long‑term use may affect calcium absorption.

When prescribing Lansoprazole, clinicians should observe several precautionary measures to ensure safe use.

- Assess renal function: adjust therapy in patients with severe impairment. - Review concomitant medications: avoid known CYP2C19 inhibitors that may increase exposure. - Monitor for infection: be alert to signs of Clostridioides difficile colitis. - Use with caution in osteoporosis: prolonged therapy may affect calcium balance. - Store at room temperature: keep in the original container, protect from moisture and light.

Lansoprazole can interact with other medicines, and some combinations should be avoided while others require monitoring.

Major Interactions (Avoid): - Ketoconazole: reduced absorption when taken together. - Atazanavir: decreased antiviral efficacy. - Clopidogrel: reduced activation leading to lower antiplatelet effect. - Warfarin: potential increase in INR and bleeding risk. - Methotrexate: increased toxicity due to reduced clearance.

Moderate Interactions (Monitor Closely): - Phenytoin: decreased plasma levels, may require dose adjustment. - Rifampin: lowers lansoprazole exposure, reducing effectiveness. - Digoxin: possible increase in serum concentration, monitor levels.